Glutathione (CAS#70-18-8), a bioactive tripeptide composed of glutamic acid, cysteine and glycine, is evolving from a niche pharmaceutical auxiliary raw material into a multi-scenario core antioxidant ingredient spanning medicine, cosmetics, dietary supplements and food additives, reshaping the global fine chemical and biomedicine supply chain amid surging public health awareness and global import & export regulatory adjustments. According to QYResearch authoritative statistics, the global glutathione market scale reached USD 361 million in 2025, and is projected to maintain a compound annual growth rate (CAGR) of 8.8% from 2026 to 2032, with the total market value hitting USD 652 million by 2032. Global annual total output of glutathione stood at roughly 7,200 metric tons in 2025, among which reduced glutathione (GSH) accounts for over 80% of total output owing to its strong direct antioxidant activity, while oxidized glutathione (GSSG) takes up the remaining market share as a stabilizer and biochemical detection reagent.
The global supply pattern has undergone drastic restructuring since early 2025. Previously, Japan’s Kyowa Hakko Bio occupied nearly 20% of the world’s total glutathione production capacity and served as a key overseas supplier for pharmaceutical-grade raw materials worldwide. However, China’s National Medical Products Administration suspended the import approval of glutathione APIs manufactured by Kyowa Hakko Bio in March 2025 due to historical data fraud and unstable quality control, directly creating a global supply gap of more than 20% in the high-purity pharmaceutical-grade segment. Following this policy adjustment, the European Union and the United States have launched follow-up qualification reviews on Japanese imported glutathione products, further tightening cross-border supply channels. Price fluctuation has become prominent across major international regions: the CFR price of pharmaceutical-grade glutathione in North America rose by 42% within six months in 2025, driven by tight inventory and downstream rigid demand from oncology adjuvant therapy and liver disease treatment; European market prices climbed 35% year-on-year, as REACH regulation raised the threshold for imported biomaterial registration and restricted low-purity synthetic-process glutathione entering the EU market. In contrast, Southeast Asia emerges as the fastest-growing consumption region, with local market demand growing at a yearly rate of 19.37%, mainly fueled by booming whitening skincare and oral anti-aging supplement industries.
China has stepped forward to become the world’s largest glutathione producer, core exporter and fastest-growing consumer market, realizing comprehensive domestic substitution of imported raw materials against the backdrop of national biomedical industrial policy layout. Driven by the Special Action Plan for High-Quality Development of Biomedical Industry (2025–2027) issued by China’s National Development and Reform Commission, Ministry of Industry and Information Technology and NMPA, high-purity glutathione and its derivatives are listed as top priority key small-molecule bioactive substances for technological breakthrough, with special technical transformation funds of RMB 1.28 billion allocated to upgrade enzymatic synthesis production lines and intelligent freeze-drying workshops for glutathione manufacturing. In 2025, China’s domestic glutathione market size reached approximately USD 187 million, accounting for 51.8% of the global total market volume, and the figure is expected to rise to USD 276 million by 2032 with a CAGR of 8.1%, outpacing the global average growth level. Domestic annual output of glutathione exceeded 4,900 metric tons in 2025, contributing 68% of the world’s total production capacity, with major manufacturers concentrated in East China and North China including Jincheng Pharmaceutical, Zhejiang Medicine, Shandong Xinhua Pharmaceutical and Shijiazhuang Enbpu Pharma. Fermentation production technology independently developed by Chinese enterprises cuts production costs by 40% compared with traditional chemical synthesis routes, laying a solid foundation for large-scale stable supply and export expansion.
A core industrial upgrading trend lies in the shift from conventional industrial and pharmaceutical grades to ultra-high-purity and customized derivative products. Ultra-purity glutathione (purity ≥99.5%) for laboratory research and biopharmaceutical precision preparation previously relied heavily on imports from Japan and the United States, while Chinese manufacturers are currently accelerating purification process iteration to break overseas technical barriers in this high-margin segment. Meanwhile, liposomal glutathione and acetylated glutathione derivatives are being industrialized in China, solving the low bioavailability defect of ordinary oral glutathione and expanding product application scenarios in high-end healthcare and medical cosmetology. Besides output expansion, Chinese producers are also strengthening green production transformation: closed-loop waste liquid recycling and low-carbon fermentation technologies are being promoted across mainstream factories, helping export products meet EU carbon border adjustment mechanism (CBAM) requirements and enhance long-term international competitiveness.
Sustainability and standardized supervision will continuously shape the long-term development trajectory of the glutathione industry globally and domestically. Natural fermentation-based glutathione is gradually replacing chemically synthesized products, as global brands prioritize raw materials with lower carbon footprints and cleaner production credentials. In China, provincial authorities have incorporated glutathione into the key cultivation catalog of biomedicine industries in 17 provincial-level administrative regions, issuing 43 targeted supportive policies in 2025 alone to standardize production qualification, quality testing and traceability management of the whole industrial chain. Looking ahead, the global glutathione market will maintain a pattern of loose supply for low-purity bulk products and tight supply for high-purity specialty grades. Chinese manufacturers will keep increasing investment in refined processing and new derivative R&D to lift product added value. Driven by persistent demand from pharmaceuticals, cosmetics, nutrition and biomedicine fields, glutathione will consolidate its position as a vital bio-based fine chemical raw material, while China will solidify its role as the global production, supply and R&D center of glutathione throughout the next decade.
